JP2021001143A - 乳び血漿改善剤 - Google Patents
乳び血漿改善剤 Download PDFInfo
- Publication number
- JP2021001143A JP2021001143A JP2019115854A JP2019115854A JP2021001143A JP 2021001143 A JP2021001143 A JP 2021001143A JP 2019115854 A JP2019115854 A JP 2019115854A JP 2019115854 A JP2019115854 A JP 2019115854A JP 2021001143 A JP2021001143 A JP 2021001143A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- cholesterol
- yeast rice
- red yeast
- chylothorax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000005911 diet Nutrition 0.000 claims abstract description 41
- 230000037213 diet Effects 0.000 claims abstract description 39
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract 4
- 229940026314 red yeast rice Drugs 0.000 claims description 75
- 206010051228 Chylothorax Diseases 0.000 claims description 53
- 239000003795 chemical substances by application Substances 0.000 claims description 39
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 241000030999 Monascus pilosus Species 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 7
- 230000006866 deterioration Effects 0.000 claims description 5
- 230000002366 lipolytic effect Effects 0.000 claims description 4
- 241000228347 Monascus <ascomycete fungus> Species 0.000 abstract description 24
- 230000037406 food intake Effects 0.000 abstract description 11
- 102000004882 Lipase Human genes 0.000 abstract 1
- 108090001060 Lipase Proteins 0.000 abstract 1
- 239000004367 Lipase Substances 0.000 abstract 1
- 235000019421 lipase Nutrition 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 85
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 50
- 210000004369 blood Anatomy 0.000 description 39
- 239000008280 blood Substances 0.000 description 39
- 239000000203 mixture Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 21
- 235000013305 food Nutrition 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 20
- 235000012000 cholesterol Nutrition 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 108010004103 Chylomicrons Proteins 0.000 description 18
- 244000113306 Monascus purpureus Species 0.000 description 17
- 235000002322 Monascus purpureus Nutrition 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 229940057059 monascus purpureus Drugs 0.000 description 16
- 240000007594 Oryza sativa Species 0.000 description 15
- 235000007164 Oryza sativa Nutrition 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 15
- 235000009566 rice Nutrition 0.000 description 15
- 238000002834 transmittance Methods 0.000 description 15
- 235000013336 milk Nutrition 0.000 description 14
- 239000008267 milk Substances 0.000 description 14
- 210000004080 milk Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
- 235000006694 eating habits Nutrition 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 244000068988 Glycine max Species 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 238000008214 LDL Cholesterol Methods 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 208000032928 Dyslipidaemia Diseases 0.000 description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 244000299461 Theobroma cacao Species 0.000 description 5
- 235000019219 chocolate Nutrition 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000005686 eating Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DYPGTLUYQZIULN-UHFFFAOYSA-N 3-(3-methoxy-5-methylanilino)propane-1-sulfonic acid Chemical compound COC1=CC(C)=CC(NCCCS(O)(=O)=O)=C1 DYPGTLUYQZIULN-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 239000004579 marble Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 244000208874 Althaea officinalis Species 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010089254 Cholesterol oxidase Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 101000801619 Homo sapiens Long-chain-fatty-acid-CoA ligase ACSBG1 Proteins 0.000 description 1
- 241000519695 Ilex integra Species 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102100033564 Long-chain-fatty-acid-CoA ligase ACSBG1 Human genes 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- 235000010634 bubble gum Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000001035 marshmallow Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000015145 nougat Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019115854A JP2021001143A (ja) | 2019-06-21 | 2019-06-21 | 乳び血漿改善剤 |
| TW109119512A TW202108156A (zh) | 2019-06-21 | 2020-06-10 | 乳糜血漿改善劑、乳糜微粒血症的抑制劑及乳糜微粒血症的改善劑 |
| PCT/JP2020/023776 WO2020256017A1 (fr) | 2019-06-21 | 2020-06-17 | Agent d'amélioration du plasma laiteux |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019115854A JP2021001143A (ja) | 2019-06-21 | 2019-06-21 | 乳び血漿改善剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021001143A true JP2021001143A (ja) | 2021-01-07 |
Family
ID=73994249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019115854A Pending JP2021001143A (ja) | 2019-06-21 | 2019-06-21 | 乳び血漿改善剤 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2021001143A (fr) |
| TW (1) | TW202108156A (fr) |
| WO (1) | WO2020256017A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022135089A (ja) * | 2021-03-04 | 2022-09-15 | 小林製薬株式会社 | コレステロールの低減剤 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09288111A (ja) * | 1996-04-23 | 1997-11-04 | Iatron Lab Inc | 生体試料の濁りを除去するための試薬 |
| WO2001006243A1 (fr) * | 1999-07-16 | 2001-01-25 | Asahi Kasei Kabushiki Kaisha | Procede de mesure d'une substance et reactif a cet usage |
| JP2012158553A (ja) * | 2011-02-01 | 2012-08-23 | Gunze Ltd | 内臓脂肪蓄積抑制剤 |
| JP2013063925A (ja) * | 2011-09-16 | 2013-04-11 | Sunway Biotech Co Ltd | 血液脂質を引き下げ、ｈｄｌコレステロールを引き上げることができる混合物とその製造方法 |
| JP2014531418A (ja) * | 2011-09-06 | 2014-11-27 | アイピー サイエンス リミテッド | 生成物および方法 |
-
2019
- 2019-06-21 JP JP2019115854A patent/JP2021001143A/ja active Pending
-
2020
- 2020-06-10 TW TW109119512A patent/TW202108156A/zh unknown
- 2020-06-17 WO PCT/JP2020/023776 patent/WO2020256017A1/fr active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09288111A (ja) * | 1996-04-23 | 1997-11-04 | Iatron Lab Inc | 生体試料の濁りを除去するための試薬 |
| WO2001006243A1 (fr) * | 1999-07-16 | 2001-01-25 | Asahi Kasei Kabushiki Kaisha | Procede de mesure d'une substance et reactif a cet usage |
| JP2012158553A (ja) * | 2011-02-01 | 2012-08-23 | Gunze Ltd | 内臓脂肪蓄積抑制剤 |
| JP2014531418A (ja) * | 2011-09-06 | 2014-11-27 | アイピー サイエンス リミテッド | 生成物および方法 |
| JP2013063925A (ja) * | 2011-09-16 | 2013-04-11 | Sunway Biotech Co Ltd | 血液脂質を引き下げ、ｈｄｌコレステロールを引き上げることができる混合物とその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020256017A1 (fr) | 2020-12-24 |
| TW202108156A (zh) | 2021-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2168440B1 (fr) | Extrait contenant de l'équol, son procédé de production, procédé d'extraction de l'équol, et aliment contenant de l'équol | |
| US20190281871A1 (en) | Chicory products containing cannabinoids | |
| US20140288187A1 (en) | Cocoa-based food products | |
| JP5261808B2 (ja) | 脂肪蓄積抑制剤、医薬品及び脂肪蓄積抑制作用を新たに付与する方法 | |
| JPH10155459A (ja) | アスタキサンチン含有飲食物 | |
| WO2020256017A1 (fr) | Agent d'amélioration du plasma laiteux | |
| US20160000110A1 (en) | Caffeine-reduced cacao composition | |
| KR101458556B1 (ko) | 프로바이오틱 혼합균주의 발효물 및 이를 포함하는 건강기능성식품 및 의약조성물 | |
| KR20100122296A (ko) | 발효차를 함유하는 혈액 순환 개선용 조성물 및 이를 포함하는 약제학적 및 건강 식품 조성물 | |
| ES2434691T3 (es) | Agente para promover la secreción de adiponectina y/o inhibir la disminución en la secreción de adiponectina | |
| KR100787003B1 (ko) | 치자 추출물을 포함하는 리파아제 억제제, 이를 포함하는기능성 식품 및 의약 조성물 | |
| KR101876534B1 (ko) | 비알코올성 지방간 질환의 예방 또는 개선용 조성물 | |
| JP2009114111A (ja) | カルシウム吸収促進剤 | |
| JP5222299B2 (ja) | 脂肪吸収抑制組成物 | |
| JP2009102270A (ja) | 脂肪代謝抑制剤 | |
| US20080220052A1 (en) | Body weight gain inhibitor | |
| TW201200148A (en) | Adiponectin production-promoting composition | |
| US20120288527A1 (en) | Antiallergic agent | |
| JP2009102276A (ja) | 抗糖尿病剤 | |
| JP2009114112A (ja) | 抗骨粗鬆症剤 | |
| JP7423731B2 (ja) | 疲労感、意欲低下または眠気の改善剤 | |
| JP2007269739A (ja) | 脂肪蓄積抑制剤およびこれを含有する飲食品 | |
| EP4289485A1 (fr) | Composition ayant un effet immunostimulant | |
| WO2023210679A1 (fr) | Composition destinée à améliorer la fonction cérébrale | |
| JP2002255839A (ja) | 抗肥満剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220506 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230509 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231003 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231201 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240305 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240605 |